None
EN
Women Still Underrepresented in Cardiovascular Trials
['.Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow', 'Class', 'Wp-Block-Co-Authors-Plus', 'Display Inline', '.Wp-Block-Co-Authors-Plus-Avatar', 'Where Img', 'Height Auto Max-Width', 'Vertical-Align Bottom .Wp-Block-Co-Authors-Plus-Coauthors.Is-Layout-Flow .Wp-Block-Co-Authors-Plus-Avatar', 'Vertical-Align Middle .Wp-Block-Co-Authors-Plus-Avatar Is .Alignleft .Alignright', 'Display Table .Wp-Block-Co-Authors-Plus-Avatar.Aligncenter Display Table Margin-Inline Auto']
News Archive - Endocrinology Advisor
Frederick Berro Rivera, M.D., from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a systematic literature review to determine the representation of women across a broad range of CV trials.
However, the female-to-male ratio was higher for obesity (median, 1.44) and pulmonary hypertension (median, 2.86) trials.
Compared with drug trials, the female-to-male ratio was higher for trials on lifestyle interventions (median, 1.51).
For clinical trials on coronary heart disease (median, 0.66), acute coronary syndrome (median, 0.79), and stroke (median, 0.74), the participation-to-prevalence ratios were low.
There was variance in representation of women in CV trials by disease state, region, intervention, and sponsor type.
['femaletomale'
'cardiovascular'
'women'
'trials'
'disease'
'heart'
'underrepresented'
'cv'
'ratio'
'coronary'
'median'
'representation']